Johnson & Johnson Company Research Report
Company Overview
Name:
Johnson & Johnson
Mission:
To redefine healthcare by connecting the best of Health & Care for every provider, for every patient, for everyone.
Founded:
1886
Founders:
Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson
Key People:
- Chairman and Chief Executive Officer: Joaquin Duato
- Executive Vice President, Global Corporate Affairs: Vanessa Broadhurst
- Executive Vice President, Chief Human Resources Officer: Peter Fasolo, Ph.D.
- Executive Vice President, Chief Legal Officer: Liz Forminard
- Executive Vice President, Innovative Medicine, R&D: John C. Reed, M.D., Ph.D.
- Executive Vice President, Worldwide Chairman, MedTech: Tim Schmid
- Executive Vice President, Chief Information Officer: James Swanson
- Executive Vice President, Worldwide Chairman, Innovative Medicine: Jennifer L. Taubert
- Executive Vice President, Chief Technical Operations and Risk Officer: Kathryn E. Wengel
- Executive Vice President, Chief Financial Officer: Joseph J. Wolk
Headquarters:
New Brunswick, New Jersey, United States
Number of Employees:
Approximately 130,000 worldwide
Revenue:
No information is available
Known For:
Leading innovations in healthcare across pharmaceuticals, medical devices, and consumer health products.
Products
Pharmaceuticals:
- TREMFYA: Treats plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
- Key Features: Dual-acting interleukin-23 inhibitor, high rates of endoscopic remission.
- RYBREVANT: Treats advanced EGFR-mutated non-small cell lung cancer.
- Key Features: Targets EGFR mutations, used in combination therapies, significant improvement in progression-free survival.
- LAZCLUZE: Investigational drug used in combination with RYBREVANT for lung cancer.
- Key Features: Shows overall survival trends versus osimertinib.
- Nipocalimab: Under regulatory review to treat antibody positive generalized myasthenia gravis.
- Key Features: High affinity and specificity to block FcRn, reduces levels of autoantibodies.
Medical Devices:
- DePuy Synthes: Focuses on orthopaedic devices.
- Key Features: Advanced orthopaedic devices, educational support for providers, diversity and inclusion initiatives.
- Teligen System: Surgical technology platform.
- Key Features: Disposable camera for enhanced visibility during minimally invasive spine surgeries.
Consumer Health:
No information is available
Recent Developments
New Products Launched:
- TREMFYA: Received FDA approval for ulcerative colitis (September 11, 2024).
- MatrixSTERNUM Fixation System: Launched by DePuy Synthes (August 29, 2024).
New Features Added:
No information is available
New Partnerships:
- Johnson & Johnson MedTech: Updated brand identity, unifying Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and CERENOVUS under the Johnson & Johnson MedTech name (September 10, 2024).
Other Notable Developments:
- Dexamethasone: Reduction in infusion-related reactions for patients with EGFR-mutated non-small cell lung cancer treated with RYBREVANT (September 10, 2024).
- Johnson & Johnson Acquired Shockwave Medical (April 5, 2024).
Johnson & Johnson continues to innovate across various sectors of healthcare, promoting diversity, equity, and inclusion, while addressing global health inequities and environmental sustainability.
This report summarizes the key information on Johnson & Johnson based on the data provided. For further details or financial information, please refer to the company's official press releases and financial reports.